Breakthrough: MDMA Therapy for PTSD Nears U.S. Approval
A study conducted by MAPS Public Benefit Corporation has shown that MDMA-assisted therapy is effective in reducing symptoms of post-traumatic stress disorder (PTSD). The company plans to submit the results to the FDA for approval to market MDMA as a treatment for PTSD when combined with talk therapy. Conventional therapies and medications only help around 50% of PTSD patients, leaving many feeling hopeless. If approved, MDMA-assisted therapy would be the first novel treatment for PTSD in over two decades. The study included a diverse group of participants and found that those who received MDMA experienced significantly greater reductions in PTSD symptoms compared to those who received a placebo. The researchers are now working on a follow-up study to examine the long-term effects of MDMA-assisted therapy.